Virtu Financial LLC Acquires Shares of 29,491 Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

Virtu Financial LLC acquired a new position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 29,491 shares of the company’s stock, valued at approximately $99,000.

Several other institutional investors have also recently made changes to their positions in AVIR. Barclays PLC boosted its holdings in Atea Pharmaceuticals by 74.5% in the third quarter. Barclays PLC now owns 177,077 shares of the company’s stock valued at $593,000 after purchasing an additional 75,624 shares during the last quarter. Zacks Investment Management acquired a new position in shares of Atea Pharmaceuticals in the 3rd quarter valued at about $80,000. State Street Corp boosted its stake in shares of Atea Pharmaceuticals by 0.7% in the third quarter. State Street Corp now owns 1,733,486 shares of the company’s stock worth $5,807,000 after buying an additional 11,566 shares during the last quarter. FMR LLC grew its holdings in Atea Pharmaceuticals by 2.8% during the third quarter. FMR LLC now owns 6,618,297 shares of the company’s stock worth $22,171,000 after acquiring an additional 182,174 shares during the period. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in Atea Pharmaceuticals in the 3rd quarter worth approximately $37,000. Hedge funds and other institutional investors own 86.67% of the company’s stock.

Wall Street Analyst Weigh In

Separately, William Blair raised Atea Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th.

Insider Buying and Selling at Atea Pharmaceuticals

In other news, Director Franklin M. Berger sold 359,606 shares of the company’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $2.85, for a total transaction of $1,024,877.10. Following the completion of the sale, the director now owns 451,897 shares of the company’s stock, valued at $1,287,906.45. This represents a 44.31 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 17.80% of the company’s stock.

Atea Pharmaceuticals Stock Performance

NASDAQ:AVIR opened at $3.13 on Friday. The stock has a market capitalization of $264.37 million, a PE ratio of -1.51 and a beta of 0.20. Atea Pharmaceuticals, Inc. has a fifty-two week low of $2.75 and a fifty-two week high of $4.60. The company has a fifty day moving average of $3.32 and a two-hundred day moving average of $3.50.

Atea Pharmaceuticals (NASDAQ:AVIR) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.13. During the same quarter last year, the company posted ($0.40) EPS. Research analysts forecast that Atea Pharmaceuticals, Inc. will post -2.01 earnings per share for the current year.

Atea Pharmaceuticals Profile

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.